<DOC>
	<DOCNO>NCT03047980</DOCNO>
	<brief_summary>The purpose research study gain preliminary understanding safety sirolimus Sturge-Weber syndrome ( SWS ) determine best outcome use assess utility sirolimus treatment cognitive impairment related Sturge-Weber syndrome .</brief_summary>
	<brief_title>Trial Sirolimus Cognitive Impairment Sturge-Weber Syndrome</brief_title>
	<detailed_description>Sirolimus administer adjunct current medication . The impact sirolimus upon cognitive function Sturge-Weber syndrome primary outcome measure . This outcome assess use panel test select base upon extensive experience test cognitive function adult child SWS Kennedy Krieger Sturge-Weber Center . Changes quantitative EEG trial , Sturge-Weber syndrome clinical neuroscore , port-wine birthmark score , impact sirolimus upon seizure assess .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Brain Stem Infarctions</mesh_term>
	<mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
	<mesh_term>Sturge-Weber Syndrome</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male female patient age 3 31 year age , inclusive . 2 . Cognitive impairment define follow : SWS cognitive neuroscore ≥ 1 3 . Ability participate direct neuropsychological developmental test . 4 . English primary language . 5 . Stable antiepileptic drug ( change medication except dose &gt; 3 month ) . 6 . Adequate renal function . GFR must great 50 ml/min/m2 determine Schwartz Formula child MDRD adult : http : //www.nkdep.nih.gov/professionals/gfr_calculators/index.htm 7 . If female child bear potential , documentation negative pregnancy test prior enrollment determine urine test require . Sexually active premenopausal female patient ( female partner male patient ) must use adequate contraceptive measure , exclude estrogen contain contraceptive , study drug . Abstinence consider adequate contraceptive measure . 8 . INR ≤1.5 ( Anticoagulation allow target INR ≤ 1.5 stable dose warfarin stable dose LMW heparin &gt; 2 week . ) 9 . Adequate liver function show : Serum bilirubin ≤ 1.5x ULN ALT AST ≤ 2.5x ULN 10 . Written inform consent accord local guideline . Local guideline subject assent also follow . 11 . Stable dose medication affect cytochrome P 450 3A4 ( CYP3A4 ) p glycoprotein ( P gp ) system least 3 month prior consent . 1 . Allergy sirolimus rapamycin analogue . 2 . Patients seizures secondary metabolic , toxic , infectious psychogenic disorder , drug abuse current seizure relate acute medical illness . 3 . Inability keep followup appointment , maintain close contact Principal Investigators , and/or complete necessary study maintain safety . 4 . Patients need immediate major surgical intervention . 5 . Concurrent severe and/or uncontrolled medical disease , could compromise participation pilot study ( e.g . uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , chronic liver renal disease , active upper GI tract ulceration , impaired restrictive pulmonary function , pneumonitis pulmonary infiltrates ) . 6 . Chronic treatment systemic steroid another immunosuppressive agent . Patients endocrine deficiency allow receive physiologic stress dose steroid necessary . Inhaled steroid allow . 7 . Known history HIV seropositivity know immunodeficiency . Testing required unless condition suspect . 8 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption sirolimus ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . A gastric tube nasogastric tube allow . 9 . Patients active , bleeding diathesis . 10 . Patients uncontrolled hyperlipidemia : fasting serum cholesterol &gt; 300 mg/dL AND fast triglyceride &gt; 2.5 x ULN . 11 . Patients major surgery significant traumatic injury within four week study entry . Patients recover side effect major surgery ( define require general anesthesia ) patient may require major surgery course pilot study . 12 . Patients prior history organ transplant . 13 . Patients receive live attenuate vaccine within one week start sirolimus pilot study . 14 . Patients history malignancy . 15 . Patients currently part participate clinical investigation investigational drug within one month prior enrollment . 16 . Patients treated felbamate , unless treatment continuous ≥ one year . 17 . Patients currently receive anticancer therapy receive anticancer therapy within four week study entry ( include chemotherapy , radiation therapy , antibody base therapy , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>31 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SWS</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>sirolimus</keyword>
</DOC>